| Product Code: ETC7654606 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Israel continued to rely heavily on imports of large molecule drug substances from top exporting countries such as Switzerland, USA, Germany, China, and Belgium. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, with limited diversification in sourcing. Despite a negative compound annual growth rate (CAGR) from 2020-24, there was a notable improvement in the growth rate from 2023-24, suggesting a potential shift in the market dynamics and increasing demand for large molecule drug substances in Israel.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Large Molecule Drug Substance CDMO Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Israel Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Israel Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs in the pharmaceutical industry |
4.2.2 Growing trend towards outsourcing manufacturing activities to contract development and manufacturing organizations (CDMOs) |
4.2.3 Technological advancements in the production of large molecule drug substances |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and compliance standards for large molecule drug manufacturing |
4.3.2 High initial capital investment and operational costs associated with setting up large molecule drug manufacturing facilities |
5 Israel Large Molecule Drug Substance CDMO Market Trends |
6 Israel Large Molecule Drug Substance CDMO Market, By Types |
6.1 Israel Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Israel Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Israel Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Israel Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Israel Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Israel Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage increase in the number of partnerships between pharmaceutical companies and CDMOs for large molecule drug manufacturing |
8.2 Average turnaround time for large molecule drug substance production |
8.3 Rate of adoption of innovative manufacturing technologies in large molecule drug production |
8.4 Number of new entrants or expansions in the Israel large molecule drug substance CDMO market |
8.5 Level of investment in research and development for improving manufacturing processes and capabilities in the market |
9 Israel Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Israel Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Israel Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Israel Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Israel Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Israel Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Israel Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |